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Abstract
Background
The UK National Health Service is striving to improve access to palliative care for patients
with advanced cancer however limited information exists on the level of palliative care sup-
port currently provided in the UK. We aimed to establish the duration and intensity of pallia-
tive care received by patients with advanced cancer and identify which cancer patients are
missing out.
Methods
Retrospective cancer registry, primary care and secondary care data were obtained and
linked for 2474 patients who died of cancer between 2010 and 2012 within a large metropoli-
tan UK city. Associations between the type, duration, and amount of palliative care by demo-
graphic characteristics, cancer type, and therapies received were assessed using Chi-
squared, Mann-Whitney or Kruskal-Wallis tests. Multinomial multivariate logistic regression
was used to assess the odds of receiving community and/or hospital palliative care com-
pared to no palliative care by demographic characteristics, cancer type, and therapies
received.
Results
Overall 64.6% of patients received palliative care. The average palliative care input was two
contacts over six weeks. Community palliative care was associated with more palliative care
events (p<0.001) for a longer duration (p<0.001). Patients were less likely to receive pallia-
tive care if they were: male (p = 0.002), aged 80 years or over (p<0.05), diagnosed with lung
cancer (p<0.05), had not received an opioid prescription (p<0.001), or had not received che-
motherapy (p<0.001). Patients given radiotherapy were more likely to receive community
only palliative care compared to no palliative care (Odds Ratio = 1.49, 95% Confidence
Interval = 1.16–1.90).
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Conclusion
Timely supportive care for cancer patients is advocated but these results suggest that older
patients and those who do not receive anti-cancer treatment or opioid analgesics miss out.
These patients should be targeted for assessment to identify unmet needs which could ben-
efit from palliative care input.
Background
For patients with advanced cancer, access to palliative care can improve quality of life and
reduce hospitalisations, aggressive anti-cancer treatment and the chance of dying in hospi-
tal [1–7]. The research evidence to support this is mainly derived from studies undertaken
in North America and is beginning to influence policy within the US [8]. Within the UK,
research in this area has been slower to progress and there is currently no evidence to draw
on from a UK National Health Service context about what represents usual care in relation
to access to palliative care for patients with advanced cancer. A key challenge is the UK
model of palliative care delivery has evolved to be inherently diverse with patients receiv-
ing palliative care across various settings ranging from the patient’s own home to outpa-
tient clinics, inpatient wards, hospices, acute hospitals and nursing homes. This makes it
difficult to establish the proportion of cancer patients receiving palliative care in these
contexts and the typical duration of care. The US research evidence also leaves questions
unanswered. It is unclear which palliative care interventions led to improvements in out-
comes, which patients would benefit most and when in the course of disease, integration
of palliative care should occur [9]. Despite these challenges, in July 2016 an Enhanced Sup-
portive Care (ESC) initiative was launched in 21 cancer centres across England under-
pinned by the US research evidence [1–7] and supported by incentives from NHS England
[10].
This study aims to establish the proportion of cancer patients receiving community or hos-
pital based palliative care before death, describe the duration and intensity of the palliative care
provided, and the associations between palliative care provision and patient characteristics.
This will enable us to benchmark local practice against the US research evidence which is driv-
ing the ESC initiative, provide a baseline against which to measure its impact and determine
which cancer patients are currently underrepresented, in terms of access to palliative care, to
help target ESC towards those who may benefit most.
Methods
Design
A retrospective analysis of deceased cancer patient data obtained from registry, primary care
and secondary care sources. An open Pseudonymiser system was used to link datasets, using
an encrypted code based on NHS numbers. Registry data was obtained from the Northern and
Yorkshire Cancer Registry (NYCR). Primary care data was obtained from SystmOne, a UK
wide medical record system used by approximately three quarters of GP practices in Leeds.
The Patient Pathway Manager (PPM), a clinical information system used at Leeds Teaching
Hospitals Trust (LTHT) to manage and coordinate care, provided secondary care data.
Ethical approval for the study was granted by the National Research Ethics Service (PR 13.
YH.0301).
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Participants
Deceased patients, registered on the NYCR and SystmOne who died of cancer between Janu-
ary 2010 and February 2012 and were at least 18 years of age at death were selected for
inclusion.
Measures
Palliative care. Community palliative care provision was calculated using GP communi-
cations within SystmOne. In the first stage, all SystmOne records for eligible patients were
extracted if they included a palliative care based Read code, or included text indicating pallia-
tive care had been received. Read codes are used within primary care in the UK as a standard
tool to record patient records, findings, and procedures [11]. In the second stage community
palliative care provision was identified as having taken place if the GP record referred to com-
munication with a hospice, or if the Read codes indicated active palliative care had taken place.
The decision as to whether a Read code indicated active palliative care was identified through
consensus between the authors CLC, MIB, and LEZ. The list of all READ codes identified,
with READ codes indicating active palliative care, are provided in S1 Table. Each unique date
in which palliative care provision was recorded within SystmOne was identified as a unique
community palliative care event.
Hospital palliative care provision was provided by PPM from their palliative care referral
database. Each unique palliative care referral date recorded on the PPM system was identified
as a unique hospital palliative care event.
Three indicators were used to define palliative care provision. The first indicator identified
if patients received palliative care and, if so, the provider of this care (community or hospital).
The remaining indicators represented the duration and intensity of palliative care received.
These were calculated using the difference (in weeks) between date of the first palliative care
event and date of death, and the number of palliative care events, respectively.
Demographic characteristics. NYCR provided the demographic information age at death,
sex, and deprivation. Deprivation was measured using the Indices of Multiple Deprivation
(IMD) quintiles (1 most deprived; 5 least deprived); a measure of neighbourhood deprivation
based on income, employment, education, health, crime, access to services, and living environ-
ment. Hospital admissions to LTHT between diagnosis and death were obtained from the PPM.
Cancer characteristics. Cancer diagnosis and cancer diagnosis date were provided by
NYCR. The first cancer diagnosis was used for multiple cancer diagnoses. Duration of illness,
was calculated by subtracting week of death from week of diagnosis.
Therapies received. SystmOne provided information on analgesic prescriptions within
the last year of life. Chemotherapy and radiotherapy data were provided by PPM.
Analysis
Frequencies and percentages were used to describe categorical data. The median and inter
quartile range were used to describe continuous data. The likelihood of independence between
categorical variables was assessed using the Pearson’s chi-squared test (χ2). Comparisons of
continuous data between categories were assessed using the Mann-Whitney test (two catego-
ries) or the Kruskal-Wallis test (three or more categories).
A multinomial multivariable logistic regression model was used to investigate the odds of
receiving community, hospital, or both palliative care, compared to no palliative care, taking
into account all demographic characteristics, cancer characteristics and therapies received.
Results are presented as odds ratios (ORs) alongside 95% confidence intervals. Subgroup anal-
ysis was performed for the multinomial multivariable logistic regression by duration of illness,
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with patients analysed separately based on the following groups: survival under 6 months, sur-
vival 6 months to two years, and survival over two years.
Only patients with complete demographic and prescription information were included in
the analysis. This reduced the cohort from 2479 to 2474 patients (Missing: IMD = 4, missing
opioid information = 1).
Results
Demographic characteristics
Table 1 shows comparisons between demographic patient characteristics and palliative care
provision. Of the 2474 patients included in the study 1597 (64.6%) received palliative care, with
a median of two contacts over a 6 week duration before death. Community palliative care was
received by 1124 patients (45.4%) and hospital palliative care was received by 990 patients
(40.0%). Approximately one in five (517/2474) patients received both community and hospital
palliative care. Patients received more palliative care events (p<0.001), for a longer duration
(p<0.001), in the community compared to hospital. Patients who received hospital palliative
care generally only received one contact. The likelihood of receiving palliative care, and the type
of palliative care received, was not significantly related to having had a hospital admission.
Provision of palliative care was significantly related to age and sex (p<0.001 and p = 0.002
respectively). Patients less likely to receive palliative care were over 80 years of age and male.
For patients who received palliative care, the number of palliative care events was significantly
related to the patient’s age (p = 0.012), with patients aged under 50 years at death receiving sig-
nificantly more palliative care events than patients aged 80 years or over (p = 0.011). There
were no significant associations between the IMD deprivation quintiles for any of the palliative
care provision outcomes assessed.
Cancer characteristics
Palliative care provision was significantly associated with both cancer type and duration of ill-
ness (both p<0.001), Table 2. Comparing no palliative care to some palliative care showed that
patients with upper gastrointestinal cancer were significantly more likely to receive palliative
care, while patients with lung cancer were significantly less likely to receive any palliative care
(p = 0.010 overall). For patients who received palliative care no significant associations were
identified between cancer type, for both duration and intensity of palliative care.
While duration of illness was not significantly associated with whether or not palliative care
was received it was significantly associated with the type of palliative care received (p<0.001).
The results suggest hospital only palliative care was more likely for patients with a short dura-
tion of illness while community palliative care was more likely for patients with a longer dura-
tion of illness. For those who received palliative care duration of illness was significantly
associated with both duration of palliative care and number of palliative care events (both
p<0.001). Patients dying within three months of first diagnosis received significantly fewer
palliative care events compared with patients dying six to nine months after diagnosis
(p = 0.007), and patients dying two or more years after diagnosis (p = 0.002). Patients who
died within three months of diagnosis received palliative care for a significantly shorter period
of time compared to all other illness durations (all p<0.001) (Table 2).
Therapies received
Palliative care provision was significantly associated with receiving chemotherapy, radiother-
apy or an opioid prescription within the last year of life (all p<0.001). For patients who
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Table 1. Demographic characteristics by palliative care provision.
Total (No.) Palliative care received (Row %) None vs.
Any p valuea
Sub-group receiving palliative care (n = 1597)
None Community only Hospital only Community &
Hospital
Palliative care events Palliative care duration (weeks)
Median IQR Mean Rank Median IQR Mean Rank
Total number of participants
2474 35.4 24.5 19.1 20.9 n/a 2 1 to
3
6 2 to 19
Palliative care provider
Community only 607 2 (i,ii) 1 to
3
767.9 7 (i,ii) 2 to 24 824.1
Hospital only 473 1 (i,iii) 1 to
1
424.1 3 (i,iii) 1 to 7 579.1
Community & Hospital 517 3 (ii,iii) 2 to
4
1178.6 10 (ii,
iii)
4 to 25 970.8
p valuesa <0.001 <0.001
Age at death (years)
<50 128 24.2 21.9 23.4 30.5  2 (i) 1 to
4
910.2 8 2 to 27 864.8
50–59 248 26.2 23.8 23.0 27.0  2 1 to
3
789.8 7 2 to 20 822.7
60–69 566 30.4 25.8 20.5 23.3  2 1 to
3
802.1 6 2 to
19.25
806.2
70–79 803 36.0 25.2 18.9 19.9 n/s 2 1 to
3
819.4 6 2 to 17 788.2
80+ 729 43.9 23.6 16.2 16.3  2 (i) 1 to
3
748.2 6 2 to 16.5 779.4
p valuesa [—————————-<0.001—————————-] <0.001 0.012 0.465
Gender
Male 1311 38 25.5 17.2 19.4  2 1 to
3
789 6 2 to 16 782
Female 1163 32.6 23.5 21.3 22.6  2 1 to
3
809.3 6 2 to 21 816.7
p valuesa [——————————0.002——————————] <0.01 0.356 0.132
IMD deprivation quintile
Quintile 1—Most
deprived
773 35.1 23.4 17.9 23.7 n/a 2 1 to
3
809 6 2 to 20 801.8
Quintile 2 480 34.4 24.8 19.2 21.7 n/a 2 1 to
3
825.6 7 3 to 20 833.2
Quintile 3 393 35.9 25.2 21.4 17.6 n/a 2 1 to
3
786.4 7 2 to 19 800.8
Quintile 4 499 36.5 25.1 18.8 19.6 n/a 2 1 to
3
775.2 6 2 to 17.5 795.6
Quintile 5—Least
deprived
329 35.9 25.2 19.8 19.1 n/a 2 1 to
3
786.6 5 1 to 15 744.2
p valuesa [——————————0.728—————————-] 0.965 0.608 0.312
At least one hospital admission at any point from first cancer diagnosis
Yes 1218 34.1 24.9 19.5 21.6 n/a 2 1 to
3
816 7 2 to 20 811.6
No 1256 36.8 24.2 18.8 20.2 n/a 2 1 to
3
781.8 6 2 to 17 786.3
p valuesa [——————————0.553——————————] 0.172 0.120 0.272
a = p values from Chi-square (categorical), Mann-Whitney (continuous, two comparison groups), or Kruskal-Wallis (continuous, three or more comparison groups)
tests
 = post-hoc z-test p values less than 0.05 (after Bonferroni correction); IQR = Interquartile range; n/s = Not significant; n/a = Not applicable; i,ii,iii,iv indicates post-hoc
comparison between pair of categories resulted in p value less than 0.05 (after Bonferroni correction)
https://doi.org/10.1371/journal.pone.0200071.t001
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received palliative care, the duration of palliative care was significantly longer for those who
received any of the three therapies (all p<0.001). Patients who received at least one opioid
prescription within the last year of life and patients who received radiotherapy received signifi-
cantly more palliative care events, compared to patients who did not receive each of the thera-
pies (p<0.001 and p = 0.035 respectively). (Table 3).
Table 2. Type and duration of cancer by palliative care provision.
Total
(No.)
Palliative care received (Row %) None vs.
Any p
valuea
Sub-group receiving palliative care (n = 1597)
None Community
only
Hospital
only
Community &
Hospital
Palliative care events Palliative care duration
(weeks)
Median IQR Mean
Rank
Median IQR Mean
Rank
Cancer diagnosis (first diagnosis)
Head and neck 111 37.8 19.8 29.7 12.6 n/s 1 1 to
2
672.3 5 1 to 13 725.8
Upper
gastrointestinal
387 28.4 25.8 21.2 24.5  2 1 to
3
827.4 7 2 to 16 811.3
Colorectal 327 34.6 25.1 15.6 24.8 n/s 2 1 to
3
853 6 2 to 20 801.1
Lung 656 40.5 24.4 15.5 19.5  2 1 to
3
789.3 6 2 to 16 767.2
Breast 235 34.5 28.5 17.0 20.0 n/s 2 1 to
4
831.2 7 1 to
30.25
828.3
Gynaecological 150 29.3 19.3 28.7 22.7 n/s 1.5 1 to
3
740.3 5 2 to
22.25
778.6
Prostate 232 35.8 28.9 15.5 19.8 n/s 2 1 to
3
796.9 9 2 to
25.5
887.4
Urological 191 34.6 22.0 25.1 18.3 n/s 2 1 to
3
754.3 6 2 to 16 766.1
Central nervous
system
59 45.8 32.2 11.9 10.2 n/s 2 1 to
4
839 10 5.25 to
19
926.1
All other cancer
sites
126 35.7 15.1 24.6 24.6 n/s 2 1 to
3
786.5 6 2 to 19 775.8
p valuesa [—————————-<0.001—————————-] 0.01 0.102 0.144
Duration of illness
0 to under 3
months
332 31.9 13.0 29.5 25.6 n/a 2 (i,ii) 1 to
3
706.9 3 (i,ii,iii,
iv,v)
1 to 5 510
3 to under 6
months
292 41.1 20.5 16.1 22.3 n/a 2 1 to
3
789.2 7 (i,vi) 2 to 14 755.9
6 to under 9
months
241 33.6 29.0 14.9 22.4 n/a 2 (i) 1 to
3
865.3 7 (ii) 2 to 21 805
9 to under 12
months
215 31.6 28.8 24.2 15.3 n/a 1 1 to
3
718.4 7 (iii) 2 to 26 825
1 to under 2 years 496 36.7 25.8 17.5 20.0 n/a 2 1 to
3
804 8 (iv) 2 to
22.25
851.6
2 or more years 898 35.6 27.2 17.0 20.2 n/a 2 (ii) 1 to
3
837.4 9 (v,vi) 2 to
32.25
888
p valuesa [—————————-<0.001—————————-] 0.159 <0.001 <0.001
a = p values from Chi-square (categorical), Mann-Whitney (continuous, two comparison groups), or Kruskal-Wallis (continuous, three or more comparison groups)
tests
 = post-hoc z-test p values less than 0.05 (after Bonferroni correction); IQR = Interquartile range; n/s = Not significant; n/a = Not applicable; i,ii,iii,iv,v indicates post-
hoc comparison between pair of categories resulted in p value less than 0.05 (after Bonferroni correction)
https://doi.org/10.1371/journal.pone.0200071.t002
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Multinomial multivariable logistic modelling
The results from the multinomial multivariable logistic regression model, presented in Table 4,
show that the type of palliative care received was significantly associated with age, gender, first
cancer diagnosis and duration of illness (see S2 Table for uni-variable logistic regression).
Significant associations were also found between receiving palliative care and receiving opi-
oids or cancer therapies. The odds of receiving palliative care (community only, hospital only,
or both community and hospital) compared with no palliative care were significantly greater
for patients who received an opioid prescription within the last year of life (Community only:
OR = 4.38, 95% CI = 3.49–5.50; Hospital only: OR = 1.82, 95% CI = 1.42–2.34; Community
and Hospital: OR = 4.34, 95% CI = 3.41–4.52) or who received chemotherapy (Community
only: OR = 1.63, 95% CI = 1.27–2.10; Hospital only: OR = 1.69, 95% CI = 1.29–2.21; Commu-
nity and Hospital: OR = 1.63, 95% CI = 1.25–2.14).
The odds of receiving community only palliative care, compared with no palliative care was
also significantly greater for patients who received radiotherapy (OR:1.49, 95% CI:1.16–1.90),
however there was no significant difference between patients who did or did not received
radiotherapy in the odds of receiving hospital only or hospital and community palliative care
compared with no palliative care.
Overall the sub group analysis (see S3 Table), reflect the overall results. For chemotherapy,
however, the subgroup analysis showed that patients who died within six months of diagnosis
had significantly lower odds of receiving hospital palliative care if they received chemotherapy
Table 3. Therapies received by palliative care provision.
Total (No.) Palliative care received (Row %) None vs.
Any p valuea
Sub-group receiving palliative care (n = 1597)
None Community only Hospital only Community &
Hospital
Palliative care events Palliative care duration
(weeks)
Median IQR Mean Rank Median IQR Mean Rank
Opioid prescription within the last year of life
Yes 222 20.5 34.0 16.5 29.0  2 1 to
4
904.0 9 3 to
26
896.3
No 655 47.1 17.1 21.2 14.6  1 1 to
2
675.9 4 1 to
12
685.0
p
valuesa
[————————-<0.001—————————] <0.001 <0.001 <0.001
Chemotherapy received
Yes 414 29.0 27.3 20.2 23.5  2 1 to
3
812.3 7 2 to
21
829.1
No 463 44.3 20.8 17.6 17.3  2 1 to
3
775.8 5 2 to
14
746.6
p
valuesa
[————————-<0.001—————————] <0.001 0.11 <0.001
Radiotherapy received
Yes 496 35.1 27.7 16.7 20.5  2 1 to
3
819.0 8 2 to
23
849.4
No 381 36.0 20.3 22.3 21.4  2 1 to
3
772.0 5 2 to
14
730.7
p
valuesa
[————————-<0.001—————————] 0.634 0.035 <0.001
a = p values from Chi-square (categorical), Mann-Whitney (continuous, two comparison groups), or Kruskal-Wallis (continuous, three or more comparison groups)
tests
 = post-hoc z-test p values less than 0.05 (after Bonferroni correction); IQR = Interquartile range; n/a = Not applicable
https://doi.org/10.1371/journal.pone.0200071.t003
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Table 4. Odds ratios (95% confidence intervals) from multinomial multivariable logistic regression comparing sources of palliative care, compared with no pallia-
tive care, by patient characteristics.
Multinomial regression (Reference = No palliative care)
Patient characteristics Community only Hospital only Community and Hospital Overall p valuea
Demographic characteristics
Age at death (years)
<50 1.08 (0.60–1.97) 2.12 (1.18–3.84) 2.55 (1.43–4.54) <0.005
50–59 1.24 (0.80–1.93) 1.96 (1.25–3.07) 2.23 (1.43–3.49)
60–69 1.21 (0.87–1.68) 1.66 (1.17–2.35) 1.75 (1.24–2.48)
70–79 1.14 (0.86–1.51) 1.37 (1.01–1.86) 1.35 (0.99–1.83)
80+ (REFERENCE) 1 1 1
Gender
Male 0.88 (0.68–1.14) 0.66 (0.50–0.86) 0.66 (0.50–0.87) <0.005
Female (REFERENCE) 1 1 1
IMD deprivation quintile
Quintile 1—Top 20% most deprived 1.00 (0.69–1.44) 0.94 (0.64–1.38) 1.32 (0.90–1.95) 0.733
Quintile 2 1.18 (0.79–1.74) 1.10 (0.73–1.67) 1.36 (0.90–2.07)
Quintile 3 1.24 (0.83–1.85) 1.20 (0.79–1.84) 1.13 (0.73–1.77)
Quintile 4 1.04 (0.71–1.53) 1.03 (0.69–1.55) 1.14 (0.75–1.72)
Quintile 5—Top 20% most affluent (REFERENCE) 1 1 1
At least one hospital admission at any point from first cancer diagnosis
Yes 0.95 (0.75–1.20) 1.01 (0.79–1.29) 1.05 (0.82–1.34) 0.902
No (REFERENCE) 1 1 1
Cancer characteristics
First diagnosis cancer site
Head and neck 0.90 (0.49–1.63) 2.57 (1.48–4.44) 0.81 (0.41–1.60) <0.001
Upper gastrointestinal 1.76 (1.20–2.58) 1.87 (1.24–2.80) 2.03 (1.36–3.02)
Colorectal 1.33 (0.89–1.97) 1.32 (0.85–2.06) 1.91 (1.27–2.88)
Trachea, bronchus and lung (REFERENCE) 1 1 1
Breast 1.13 (0.71–1.80) 1.04 (0.62–1.75) 0.97 (0.59–1.61)
Gynaecological 1.12 (0.63–1.97) 2.18 (1.27–3.74) 1.57 (0.89–2.77)
Prostate 1.40 (0.88–2.20) 1.61 (0.95–2.70) 1.89 (1.15–3.12)
Urological 1.26 (0.79–2.01) 2.33 (1.47–3.71) 1.61 (0.98–2.64)
Central nervous system 1.31 (0.66–2.57) 0.66 (0.27–1.61) 0.52 (0.20–1.35)
All other cancer sites 0.70 (0.38–1.28) 1.46 (0.85–2.51) 1.33 (0.77–2.32)
Duration of illness
0 to under 3 months 0.87 (0.56–1.35) 2.76 (1.88–4.06) 2.37 (1.58–3.53) <0.001
3 to under 6 months 0.80 (0.54–1.19) 0.97 (0.64–1.47) 1.21 (0.81–1.81)
6 to under 9 months 1.29 (0.87–1.92) 1.02 (0.65–1.62) 1.37 (0.89–2.10)
9 to under 12 months 1.36 (0.90–2.05) 1.65 (1.08–2.54) 0.95 (0.58–1.54)
1 to under 2 years 0.98 (0.72–1.33) 1.01 (0.72–1.41) 1.00 (0.72–1.39)
2 or more years (REFERENCE) 1 1 1
Therapies received
Opioid prescription within the last year of life
Yes 4.38 (3.49–5.50) 1.82 (1.42–2.34) 4.34 (3.41–5.52) <0.001
No (REFERENCE) 1 1 1
Chemotherapy received
Yes 1.63 (1.27–2.10) 1.69 (1.29–2.21) 1.63 (1.25–2.14) <0.001
No (REFERENCE) 1 1 1
(Continued)
Access to palliative care for patients with advanced cancer: A longitudinal population analysis
PLOS ONE | https://doi.org/10.1371/journal.pone.0200071 August 8, 2018 8 / 12
(OR = 0.56, 95% CI = 0.33–0.97) or radiotherapy (OR = 0.40, 95% CI = 0.24–0.68). This sug-
gests that duration of illness may be a moderator in the relationship between receiving chemo-
therapy or radiotherapy and receiving palliative care, that is, patients diagnosed late may be
less likely to receive chemotherapy or radiotherapy and hospital palliative care.
Discussion
Two thirds of cancer patients in our study received some form of palliative care before death.
This proportion is consistent with other studies undertaken in the US and Canada [12–14].
Lack of engagement with palliative care is not necessarily synonymous with unmet need. A
study exploring carers’ insights into palliative care involvement among cancer patients found
lack of engagement may relate to individual preference or lack of a perceived need by the can-
cer patient [12]. Distinguishing such patients from those who would welcome and benefit
from palliative care is reliant on effective clinical assessment and communication and the
opportunity to revisit discussions about palliative care throughout the cancer journey.
Our finding that patients over 80 years of age were less likely to receive palliative care is
consistent with the existing understanding that in the UK only 16 per cent of patients receiving
specialist palliative care are aged 85 or over, although 39 per cent of deaths occur in this age
group [15] and previous evidence showing that younger cancer patients were more likely to
access inpatient hospice services [16]. Whether this implies younger people have greater sup-
port needs or are more effective in accessing support is unclear but nevertheless this suggests
older patients in particular may benefit from more proactive assessment.
Overall receiving chemotherapy, radiotherapy or an opioid were the most important factors
associated with receiving community palliative care, and important factors associated with
receiving hospital palliative care, though duration of illness may play a role in the likelihood of
receiving these services. Being in regular contact with oncology services may therefore facili-
tate access to palliative care, particularly for those diagnosed at least six months before death.
This finding may also contribute to our understanding about why having a cancer diagnosis
has traditionally been, and continues to be, the main determinant of access to specialist pallia-
tive care services [16]. This finding suggests that efforts to improve access to palliative care
should focus on those patients who have never received chemotherapy or radiotherapy or
whose treatment has ended.
Patients who had received a prescription for an opioid were also more likely to access pallia-
tive care, though it is not clear whether the opioid prescription drives the palliative care referral
or that palliative care improves access to an opioid analgesic. A multicentre study of 1450
patients with cancer pain comparing oncology care alone with early integration of palliative
care alongside oncology care found that early access to palliative care was associated with a
31% reduced risk of suffering from severe pain [17] which supports the hypothesis that
Table 4. (Continued)
Multinomial regression (Reference = No palliative care)
Patient characteristics Community only Hospital only Community and Hospital Overall p valuea
Radiotherapy received
Yes 1.49 (1.16–1.90) 0.92 (0.71–1.18) 1.22 (0.94–1.57) <0.005
No (REFERENCE) 1 1 1
a = p value from the likelihood ratio test based on Chi-square statistics
 = Significant at the 5% level (2-tailed)
https://doi.org/10.1371/journal.pone.0200071.t004
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palliative care could be a mechanism through which to access opioid analgesia. In a recent
study we found that access to an opioid was also related to age and cancer diagnosis, possibly
suggesting that other mediators or moderator factors may explain this association [18]. Further
research is needed to fully understand the nature of the association between opioid prescrip-
tions and palliative care.
The average duration of palliative care involvement in our study was six weeks and the average
number of contacts was two. This is a relatively short period of time and a surprisingly low dose
intensity in relation to the level of engagement the US research evidence suggests is optimal [1–5].
The interventions in the US trials varied but common characteristics were an assessment and sev-
eral follow up consultations over a period of 3–6 months. We found that the duration of hospital
palliative care was even shorter and provided on fewer occasions than community palliative care. A
greater understanding is needed about the outcomes associated with the current level of palliative
care input to establish which benefits would be derived from earlier more intensive involvement.
This study has limitations. First, the population is derived from a single UK city, and although
we have been able to determine the population is broadly representative of the UK cancer popula-
tion in terms of prevalence of cancer type, age, sex, and survival, the extent to which palliative care
involvement is representative of national activity is harder to determine. Leeds has two large hos-
pices and a hospital palliative care team so is relatively well provisioned in terms of palliative care
and the level of access reported here may consequently be higher than elsewhere in the UK. The
data used in this study are derived from a live clinical system and as such are likely to represent
errors or omissions inherent within that system. We also acknowledge that we exercised caution
in selecting the read codes to identify community palliative care involvement and may mean the
extent of community palliative care involvement could be higher than reported here.
Conclusion
The study provides much needed evidence to support the implementation of the enhanced
supportive care initiative across the UK National Health Service. We have for the first time
reported duration of palliative care and intensity of palliative care input in relation to cancer
patient characteristics and context of palliative care within the UK NHS. Timely supportive
care for all cancer patients is advocated but results from this study suggest that older patients
and those who do not receive cancer therapies miss out. These patients should be targeted for
screening to identify palliative care needs. This information enables benchmarking of UK
practice against the international research evidence and identify which patients are currently
under represented in terms of access to palliative care.
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